China Largest Factory manufacturer supply Acitretin CAS 55079-83-9 CAS NO.55079-83-9

Acitretin Basic information Product Name: Acitretin Synonyms: Acritretin CAS: 55079-83-9 MF: C21H26O3 MW: 326.43 EINECS: 259-474-4 Product Categories: Inhibitors;API;Active Pharmaceutical Ingredients;Various Metabolites and Impurities;Aromatics;Soriatane;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Retinoids;Intracellular receptor Mol File: 55079-83-9.mol   Acitretin Chemical Properties Melting point  228-230°C Boiling point  404.46°C (rough estimate) density  1.1348 (rough estimate) refractive index  1.4700 (estimate) storage temp.  -20°C solubility  Practically insoluble in water, sparingly soluble in tetrahydrofuran, slightly soluble in acetone and in ethanol (96 per cent), very slightly soluble in cyclohexane. pka 4.72±0.33(Predicted) form  powder λmax 352nm(MeOH)(lit.) Merck  14,112 Stability: LIGHT SENSITIVE CAS DataBase Reference 55079-83-9(CAS DataBase Reference)

Our Factories production lines

                                                   Our Factories R&D ability

                        Our Factories warehouse 

                       Our Factories glory 

                                                                    Group profiles

Leader Biochemical Group is a large leader incorporated industry manufacturers and suppliers of advanced refined raw materials From the year of 1996 when our factory was put into production to year of 2020, our group has successively invested in more than 52 factories with shares and subordinates.We focus on manufacture Pharm & chemicals, functional active ingredients, nutritional Ingredients, health care products, cosmetics, pharmaceutical and refined feed, oil, natural plant ingredients industries to provide top quality of GMP standards products.All the invested factories' product lines cover API and intermediates, vitamins, amino acids, plant extracts, daily chemical products, cosmetics raw materials, nutrition and health care products, food additives, feed additives, essential oil products, fine chemical products and agricultural chemical raw materials And flavors and fragrances. Especially in the field of vitamins, amino acids, pharmaceutical raw materials and cosmetic raw materials, we have more than 20 years of production and sales experience. All products meet the requirements of high international export standards and have been recognized by customers all over the world. Our manufacture basement & R&D center located in National Aerospace Economic & Technical Development Zone Xi`an Shaanxi China. Now not only relying on self-cultivation and development as well as maintains good cooperative relations with many famous research institutes and universities in China. Now, we have closely cooperation with Shanghai Institute of Organic Chemistry of Chinese Academy of Science, Beijing Institute of Material Medical of Chinese Academy of Medical Science, China Pharmaceutical University, Zhejiang University. Closely cooperation with them not only integrating Science and technology resources, but also increasing the R&D speed and improving our R&D power. Offering Powerful Tech supporting Platform for group development. Keep serve the manufacture and the market as the R&D central task, focus on the technical research.  Now there are 3 technology R & D platforms including biological extract, microorganism fermentation and chemical synthesis, and can independently research and develop kinds of difficult APIs and pharmaceutical intermediates. With the strong support of China State Institute of Pharmaceutical Industry (hereinafter short for CSIPI), earlier known as Shanghai Institute of Pharmaceutical Industry (SIPI), we have unique advantages in the R & D and industrialization of high-grade, precision and advanced products.  Now our Group technical force is abundant, existing staff more that 1000 people, senior professional and technical staff accounted for more than 50% of the total number of employees, including 15 PhD research and development personnel, 5 master′ S degree in technical and management personnel 9 people. We have advanced equipment like fermentation equipment and technology also extraction, isolation, purification, synthesis with rich production experience and strict quality control system, According to the GMP required, quickly transforming the R&D results to industrial production in time, it is our advantages and our products are exported to North and South America, Europe, Middle East, Africa, and other five continents and scale the forefront in the nation, won good international reputation.  We believe only good quality can bring good cooperation, quality is our key spirit during our production, we are warmly welcome clients and partner from all over the world contact us for everlasting cooperation, Leader will be your strong, sincere and reliable partner in China.

Acitretin Basic information Product Name: Acitretin Synonyms: ;Acritretin CAS: 55079-83-9 MF: C21H26O3 MW: 326.43 EINECS: 259-474-4 Product Categories: Inhibitors;API;Active Pharmaceutical Ingredients;Various Metabolites and Impurities;Aromatics;Soriatane;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Retinoids;Intracellular receptor Mol File: 55079-83-9.mol   Acitretin Chemical Properties Melting point  228-230°C Boiling point  404.46°C (rough estimate) density  1.1348 (rough estimate) refractive index  1.4700 (estimate) storage temp.  -20°C solubility  Practically insoluble in water, sparingly soluble in tetrahydrofuran, slightly soluble in acetone and in ethanol (96 per cent), very slightly soluble in cyclohexane. pka 4.72±0.33(Predicted) form  powder λmax 352nm(MeOH)(lit.) Merck  14,112 Stability: LIGHT SENSITIVE CAS DataBase Reference 55079-83-9(CAS DataBase Reference)

Product information

Chenodeoxycholic acid Basic information Uses Product Name: Chenodeoxycholic acid Synonyms: (R)-4-((3R,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid;(R)-4-((3R,5S,7R,10S,13R)-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid;URSODEOXYCHOLOC ACID,3,7-dihydroxy-,(3-alpha,5-beta,7-alpha)-cholan-24-oicaci;5β-Cholanic acid-3α,7α-diol Chenodiol;CDCA;CHENODEOXYCHOLIC ACID;CHENODESOXYCHOLIC ACID;CHENODIOL CAS: 474-25-9 MF: C24H40O4 MW: 392.57 EINECS: 207-481-8 Product Categories: Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Intracellular receptor Mol File: 474-25-9.mol   Chenodeoxycholic acid Chemical Properties Melting point  165-167 °C (lit.) alpha  12 º (c=1, CHCl3) Boiling point  437.26°C (rough estimate) density  0.9985 (rough estimate) refractive index  1.4460 (estimate) Fp  9℃ storage temp.  room temp solubility  PRACTICALLY INSOLUBLE form  Powder pka pKa 4.34 (Uncertain) color  White to off-white Water Solubility  PRACTICALLY INSOLUBLE Merck  13,2062 BRN  3219887 InChIKey RUDATBOHQWOJDD-BSWAIDMHSA-N CAS DataBase Reference 474-25-9(CAS DataBase Reference) EPA Substance Registry System Chenodiol (474-25-9)   Safety Information Hazard Codes  Xn Risk Statements  63 Safety Statements  22-24/25-45-36/37 RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution WGK Germany  2 RTECS  FZ1980000 HS Code  29181990 MSDS Information Provider Language 3alpha,7alpha-Dihydroxy-5beta-cholanic acid English SigmaAldrich English ACROS English   Chenodeoxycholic acid Usage And Synthesis Uses Chenodeoxycholic acid is a bile acid synthesized in the liver from cholesterol. henodeoxycholic acid has been used in a study to assess its effects as a long-term replacement therapy for cerebrotendinous xanthomatosis (CTX). It has also been used in a study to investigate its effects on the small-intestinal absorption of bile acids in patients with ileostomies. Description Chenodeoxycholic acid is the first agent to be introduced into the US market for the treatment of radiolucent gallstones. Large scale clinical trials have demonstrated the safety and efficacy of this agent. Chenodeoxycholic acid reduces the biliary concentration of cholesterol relative to that of bile acids and phospholipid, reducing the saturation and thus the lithogenicity of the bile. Success rates in dissolving gallstones are in the range of 50-70% within 4-24 months of treatment. Continuation of the drug after stone dissolution may be required to prevent reoccurrence. Chenodeoxycholic acid is the 7α-isomer of ursodeoxycholic acid which was introduced into the European market in 1978. chenodeoxycholic acid structure Chemical Properties Off-White Solid Originator Rowell (USA) History Chenodeoxycholic acid was isolated in 1924 from goose gall by Adolf Windaus and human gall by Heinrich Wieland.Its complete structural configuation was elucidated by Hans Lettre at the University of Gottingen. In 1968, William Admirand and Donald Small at Boston University Medical School established that in patients with gallstones their bile was saturated with cholesterol, sometimes even exhibiting microcrystals, whereas this was not the case in normal people.It was then found that biliary levels of cholic acid and chenodeoxycholic acid were lower in patients with cholesterol gallstones than in normal people. Leslie Thistle and John Schoenfield at the Mayo Clinic in Rochester, Minnesota, then administered individual bile salts by mouth for four months and found that chenodeoxycholic acid reduced the amount of cholesterol in the bile.This led to a national collaborative study in the United States, which confirmed the effectiveness of chenodeoxycholic acid in bringing about dissolution of gallstones in selected patients. However, recent developments such as laparoscopic cholecystectomy and endoscopic biliary techniques have curtailed the role of chenodeoxycholic acid and ursodeoxycholic acid in the treatment of cholelithiasis. Uses Chenodeoxycholic acid is a bile acid that induces apoptosis through protein kinase C signaling pathways.It is a major bile acid in many vertebrates, occurring as the N-glycine and/or N-taurine conjugate. With other bile acids, forms mixed micelles with lecithin in bile which solubilize cholesterol and thus facilitates its excretion.Bile acids are essential for solubilization and transport of dietary lipids, are the major products of cholesterol catabolism, and are physiological ligands for farnesoid X receptor (FXR), a nuclear receptor that regulates genes involved in lipid metabolism.They are also inherently cytotoxic, as physiological imbalance contributes to increased oxidative stress. Bile acid-controlled signaling pathways are promising novel targets to treat such metabolic diseases as obesity, type II diabetes, hyperlipidemia, and atherosclerosis. Chenodeoxycholic acid is widely utilized in therapeutic applications. It is applied in medical therapy to dissolve gallstones. It is employed in the treatment of cerebrotendineous xanthomatosis. It is used to treat constipation and cerebrotendineous xanthomatosis. It acts as a urea receptor in supramolecular chemistry which can contain anions. It is a staining additive commonly used with ruthenium or organic photo-sensitizers in the preparation of staining solutions for dye solar cells. Chenodeoxycholic Acid is a staining additive commonly used with ruthenium or organic photo-sensitizers in the preparation of staining solutions for Dye Solar Cells. This co-adsorbent will prevent dye aggregation on the semiconductor surface, reducing losses in the solar cell's operation. Chenodeoxycholic Acid is a white solid added with the dye powder to the solvent while preparing staining solutions. The concentration of co-adsorbent is typically 10 fold the dye concentration. Chenodeoxycholic acid has been used in a study to assess its effects as a long-term replacement therapy for cerebrotendinous xanthomatosis (CTX). It has also been used in a study to investigate its effects on the small-intestinal absorption of bile acids in patients with ileostomies. Chenodeoxycholic acid (CDCA) is a hydrophobic primary bile acid that activates nuclear receptors involved in cholesterol metabolism.EC50 concentrations for activation of FXR range from 13-34 μM.In cells, CDCA also binds to bile acid binding proteins (BABP) with a reported stoichiometry of 1:2.CDCA toxicity is linked to increased cellular glutathione levels and increased oxidative stress. Exposure of cells to excess CDCA contributes to liver and intestinal cancers. Uses anticholithogenic, antilipemic agent Uses A major bile acid in many vertebrates, occurring as the N-glycine and/or N-taurine conjugate. With other bile acids, forms mixed micelles with lecithin in bile which solubilize cholesterol and thus fa cilitates its excretion. Fcilitates fat absorption in the small intestine by micellar solubilization of fatty acids and monoglycerides. Anticholelithogenic. Epimeric with Ursodiol. Uses An apoptosis inducer via PKC-dependent signalling pathway. Manufacturing Process To 1,400 ml of an approximately 50% water/triglycol solution of the potassium salt of chenodeoxycholic acid, obtained by the Wolff-Kishner reduction (using hydrazine hydrate and potassium hydroxide) from 50 g of 7- acetyl-12-ketochenodeoxycholic acid, 220 ml of dilute hydrochloric acid is added to bring the pH to 2. The solution is stirred and the crude chenodeoxycholic acid precipitates. The precipitate is recovered and dried to constant weight at about 60°C. About 36 g of the crude chenodeoxycholic acid, melting in the range of 126°-129°C, is obtained. 25 g of crude chenodeoxycholic acid so obtained is dissolved in 750 ml of acetonitrile while stirring and heating. 3 g of activated charcoal is added and then removed by suction filtering. The resulting liquid filtrate is cooled, the pure chenodeoxycholic acid crystallizing out. The crystals are recovered by suction filtering and the recovered crystals dried under vacuum. The yield is 19 g of pure chenodeoxycholic acid with a melting range of 168°-171°C. Brand name CHEWM Therapeutic Function Gallostone dissolving agent World Health Organization (WHO) Chenodeoxycholic acid was introduced in 1975 for the treatment of cholelithiasis. It is available in several countries and the World Health Organization is not aware that registration has been refused in any other country. General Description Chenodeoxycholic acid is a bile acid synthesized in the liver from cholesterol. Purification Methods This major bile acid in vertebrates (~80mg) is chromatographed on silica gel (5g) and eluted with CHCl3/EtOAc (3:2) and crystallised from EtOAc/hexane. It has IR: max 1705 cm-1(CHCl3). It also crystallises from EtOAc, EtOAc/heptane after purifying via the poorly soluble Na and K salt if necessary. [Kametani et al. J Org Chem 4 7 2331 1982, Beilstein 10 IV 1604.]   Chenodeoxycholic acid Preparation Products And Raw materials Raw materials Ethanol-->Sodium carbonate-->Barium chloride-->Hydrochloric acid alcohol-->Sodium cholate-->Hydrazine hydrate-->Potassium hydroxide Preparation Products Ursodeoxycholic acid-->squalamine-->CHENODEOXYCHOLIC ACID SODIUM-->TAUROCHENODEOXYCHOLIC ACID SODIUM SALT